Regeneron's Immunotherapy Is Given Priority Review for Treatment of New Lung Cancer Patients
The Food and Drug Administration on Thursday accepted an application from Regeneron (NASDAQ: REGN) that could make Libtayo a new treatment option for a specific group of freshly diagnosed lung cancer patients in six months or less. Libtayo is one of several antibodies Sanofi (NASDAQ: SNY) markets in partnership with Regeneron.
The agency has agreed to a priority review of Regeneron's application for the treatment of first-line non-small cell lung cancer (NSCLC) patients with tumor cells that express Libtayo's target, PD-L1, at least half of the time. The agency set an action date for Feb. 28, 2021, which is four months sooner than it would have been without priority status.
Image source: Getty Images.
Source Fool.com
